Behavioral Health Business March 25, 2025
The Drug Enforcement Administration (DEA) and the U.S. Department of Health and Human Services (HHS) have delayed the finalization of a rule meant to lock in addiction treatment-related telehealth flexibilities first implemented during the COVID-19 pandemic.
On March 20, the agencies released the text of a final rule that pushed back the effective date of another final rule entitled “Expansion of Buprenorphine Treatment via Telemedicine Encounter” to the end of 2025. It was previously slated to go into effect on Feb. 18, 2025. That was until Jan. 20, when the Trump administration announced all pending regulations were on freeze until they were reviewed.
Following that review, the administration announced a new effective date for the rule of March 21....
Today's Sponsors
Today's Sponsor